Pricing Log in Create free account
Friday 6 November 2026 Export RXRX’s income statement to Excel — free account

Recursion Pharmaceuticals, Inc.

RXRX Healthcare Biotechnology

Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.

Revenue
+258.5%
EPS
+39.1%
Free cash flow
+33.8%
Total debt
−99.2%

Quarter to September 2026, against a year earlier

3.53 0.03 +0.86%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−4.6×
Dividend yield
—
F-score
3/9
Altman Z
0.37
Beneish M
−1.72
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Recursion Pharmaceuticals, Inc. (RXRX) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Recursion Pharmaceuticals, Inc. (RXRX) trades at a EV/Sales of 19.8×. Over the past ten years it has ranged from 7.1× (March 2026) to 576× (July 2021); the current reading is higher than 16% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 14.6× (32.55%)
FY2024 21.7× (41.72%)
FY2023 37.2× 91.29%
FY2022 19.4× (92.15%)
FY2022 248× 6.40%
FY2021 233× 193.76%
FY2021 79.2× 0.00%
FY2020 79.2× 0.00%
FY2020 79.2× 0.00%
FY2019 79.2× 0.00%

Quarterly newest first

Period EV/Sales Change
Sep 2026 24.7× (3.71%)
Jun 2026 25.7× 75.31%
Mar 2026 14.6× 0.14%
Dec 2025 14.6× (58.26%)
23 more quarters

Against its own ten years

Low 7.1× High 576×
Ten-year median 28.6×
Current reading's percentile 16

EV/Sales against peers

Company EV/Sales
PHVS Pharvaris N.V. compare n/m
MBX MBX Biosciences, Inc. compare n/m
BHVN Biohaven Ltd. compare 2.2×
ADMA ADMA Biologics Inc compare 5.8×
VCEL Vericel Corporation compare 7.6×
RXRX Recursion Pharmaceuticals, Inc. 19.8×
PVLA Palvella Therapeutics, Inc. compare 48.1×
NAMS NewAmsterdam Pharma Company N.V. compare 66.6×
CLDX Celldex Therapeutics, Inc. compare 1,691×
Biotechnology industry median 9.0×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on RXRX